142 related articles for article (PubMed ID: 21395370)
1. Potential of Toll-like receptor 9 agonists in combined anticancer immunotherapy strategies: synergy of PAMPs and DAMPs?
Holtick U; Klein-Gonzalez N; von Bergwelt-Baildon MS
Immunotherapy; 2011 Mar; 3(3):301-4. PubMed ID: 21395370
[No Abstract] [Full Text] [Related]
2. [Biotherapy of solid tumors].
Moiseenko VM
Vopr Onkol; 1998; 44(1):120-5. PubMed ID: 9578746
[No Abstract] [Full Text] [Related]
3. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer.
Krieg AM
Oncogene; 2008 Jan; 27(2):161-7. PubMed ID: 18176597
[TBL] [Abstract][Full Text] [Related]
4. CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy.
Murad YM; Clay TM; Lyerly HK; Morse MA
Expert Opin Biol Ther; 2007 Aug; 7(8):1257-66. PubMed ID: 17696823
[TBL] [Abstract][Full Text] [Related]
5. [Carcinogenesis and immunobiology of tumors. Scientific and clinical aspects].
Granov AM; Molchanov OE
Vopr Onkol; 2008; 54(4):401-9. PubMed ID: 18942393
[No Abstract] [Full Text] [Related]
6. Toll-like receptor 9 agonists as cancer therapeutics.
Holtick U; Scheulen ME; von Bergwelt-Baildon MS; Weihrauch MR
Expert Opin Investig Drugs; 2011 Mar; 20(3):361-72. PubMed ID: 21254877
[TBL] [Abstract][Full Text] [Related]
7. [Oncology update '89. I].
Pfreundschuh M
Med Klin (Munich); 1989 Nov; 84(11):542-7. PubMed ID: 2687674
[No Abstract] [Full Text] [Related]
8. [Chemo- and immunotherapy of colorectal cancer].
Klein HO
Internist (Berl); 1991 Jun; 32(6):348-53. PubMed ID: 1880013
[No Abstract] [Full Text] [Related]
9. 4th Symposium on Advances in Cancer Immunology and Immunotherapy, November 29-December 1, 2018, Athens, Greece.
Fortis SP; Kotsakis A; Le Tourneau C; Tsitsilonis OE; Georgoulias V; Baxevanis CN
Cancer Immunol Immunother; 2019 Aug; 68(8):1391-1400. PubMed ID: 31309256
[No Abstract] [Full Text] [Related]
10. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help.
Garay RP; Viens P; Bauer J; Normier G; Bardou M; Jeannin JF; Chiavaroli C
Eur J Pharmacol; 2007 Jun; 563(1-3):1-17. PubMed ID: 17383632
[TBL] [Abstract][Full Text] [Related]
11. Principles of psychoneuroendocrinoimmunotherapy of cancer.
Lissoni P; Rovelli F
Immunotherapy; 2012 Jan; 4(1):77-86. PubMed ID: 22150002
[TBL] [Abstract][Full Text] [Related]
12. Harnessing innate immunity to suppress lymphoma.
Stevenson FK; Johnson PW
J Clin Oncol; 2010 Oct; 28(28):4295-6. PubMed ID: 20697076
[No Abstract] [Full Text] [Related]
13. [Adjuvant treatment in rectal cancer].
Lise M; Nitti D; Chemello F; Zane D; Taboga L; De Carli GL; Bachi V; Civalleri D; Bonalumi U
Ann Ital Chir; 1992; 63(3):321-32. PubMed ID: 1443998
[No Abstract] [Full Text] [Related]
14. Adjuvant immunotherapy for cervical cancer. Two randomized controlled studies using OK-432 or sizofiran.
Okamura K; Yajima A; Noda K
J Chemother; 1989 Jul; 1(4 Suppl):1222-4. PubMed ID: 16312843
[No Abstract] [Full Text] [Related]
15. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
[TBL] [Abstract][Full Text] [Related]
16. Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?
Zhang L; Dermawan KT; Jin ML; Xiong SD; Chu YW
Med Hypotheses; 2008 Nov; 71(5):802-4. PubMed ID: 18691831
[TBL] [Abstract][Full Text] [Related]
17. The impact of cytokines on high dose chemotherapy followed by transplantation of purified and ex vivo expanded peripheral blood stem cells: achieving a state of minimal residual disease for tumor immunotherapy with cytokine gene transfected cells.
Mertelsmann R
Eur Cytokine Netw; 1995; 6(2):79-82. PubMed ID: 7578991
[No Abstract] [Full Text] [Related]
18. Immunotherapy in anticancer responses.
Whelan M
Curr Opin Mol Ther; 2004 Feb; 6(1):8-9. PubMed ID: 15011775
[No Abstract] [Full Text] [Related]
19. Chemoimmunotherapy.
Emens LA
Cancer J; 2010; 16(4):295-303. PubMed ID: 20693839
[TBL] [Abstract][Full Text] [Related]
20. Biological response modifiers (BRM), chemotherapy, and activated cytotoxic leukocyte subsets: strategies for rational design of apheresis-based cancer immunotherapies.
Stevenson HC; Klein HG
Prog Clin Biol Res; 1990; 337():559-65. PubMed ID: 2353018
[No Abstract] [Full Text] [Related]
[Next] [New Search]
